Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Technologies Stock Is Sinking Today

By George Budwell – Sep 13, 2021 at 11:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A lost supply agreement for a partner's COVID-19 vaccine is hurting the biotech's shares today.

What happened

Dynavax Technologies (DVAX -2.31%), a mid-cap vaccine developer, saw its shares sink by as much as 15% in premarket trading Monday morning. The biotech's shares hit the skids in early morning action today after the company's French partner Valneva SE (INRL.F) announced that the U.K. government had terminated the supply agreement for its COVID-19 vaccine candidate known as VLA2001.

Dynavax's shares are taking a big hit from this news because the experimental vaccine uses the biotech's adjuvant CpG 1018. An adjuvant is a molecule used to boost the immune response of a vaccine. As of 10 a.m. EDT on Monday, Dynavax's shares are still down by a hefty 13% in the wake of this news and Valneva's equity is faring even worse, with the biopharma's American depositary receipt shedding approximately 40% of its value on this update.

Vaccine vial being tested in laboratory.

Image source: Getty Images.

So what

Dynavax's brain trust largely downplayed this news during the company's press release on the matter, perhaps for good reason. In the grand scheme of things, this supply agreement termination probably won't amount to a major loss for the biotech. Dynavax, in fact, reiterated this morning that it still expects to generate approximately $300 million to $400 million in 2021 aggregate revenue from its various supply agreements for CpG 1018. That's a respectable chunk of change for a biotech with a market cap of less than $1.7 billion at current levels. 

Now what

Is Dynavax stock a bad-news buy? Investors seem to be taking this news to mean that the biotech's other supply agreements for CpG 1018 may now be in danger. As there is no actual evidence to back up this assertion, shareholders may want to take this unfortunate update in stride. In short, if you liked Dynavax's stock before this news, there's no reason to suddenly change your mind. Therefore, this beaten-down biotech may indeed be worth scooping up on this double-digit pullback. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Stock Quote
Dynavax Technologies
$12.05 (-2.31%) $0.28
Valneva SE Stock Quote
Valneva SE
$6.80 (%)

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.